Nefopam Controlled Release Formulation for ADHD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional nefopam preparations have a short elimination half-life, leading to difficulty in maintaining analgesic efficacy and an increased frequency of adverse drug reactions due to plasma peak concentrations, especially when administered parenterally, and existing treatments for conditions like ADHD and anxiety disorders have side effects.
Innovation Solution
The use of nefopam, particularly its (+) enantiomer, in controlled release formulations to extend therapeutic effects and reduce side effects, including combination with other drugs like psycho-stimulants or monoamine reuptake inhibitors, for treating affective disorders such as ADHD, anxiety disorders, and eating disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional release preparations of nefopam are administered three times daily, then analgesic efficacy can be maintained, but the frequency of adverse drug reactions increases due to plasma peak concentrations
Solution Approach 1:
The patent applies periodic action by using controlled release technology to deliver nefopam at regulated intervals, transforming the dosing pattern from three times daily to once or twice daily while maintaining therapeutic levels and reducing peak concentration-related adverse effects
Solution Approach 2:
The patent changes the release rate parameter of nefopam from immediate release to controlled release, thereby altering the plasma concentration profile to reduce peak levels while maintaining adequate therapeutic levels over extended periods
2Reliability
If dose escalation of nefopam is performed to maintain analgesic efficacy, then pain relief is improved, but the frequency of adverse drug reactions increases
Solution Approach 1:
The patent changes the release kinetics parameter from immediate to controlled release, allowing lower total doses to achieve the same therapeutic effect while reducing adverse reactions, thereby resolving the need for dose escalation
3Speed
If parenteral delivery of therapeutic doses of nefopam is used for rapid pain relief, then analgesic onset is improved, but adverse effects on pulse and blood pressure occur
Solution Approach 1:
The patent uses controlled release to create a gradual, periodic delivery of nefopam, avoiding the sudden plasma spike from parenteral delivery while maintaining adequate analgesic onset through optimized release kinetics
Solution Approach 2:
The controlled release formulation acts as an intermediary between immediate parenteral delivery and oral administration, providing a controlled transition that achieves rapid enough onset while filtering out the harmful peak concentration effects
4Reliability
If existing treatments for ADHD and anxiety disorders are used, then therapeutic effects are achieved, but side effects occur
Solution Approach 1:
The patent changes the pharmacokinetic parameters of nefopam through controlled release formulation, creating a smoother concentration-time profile that reduces side effects while maintaining therapeutic efficacy for ADHD and anxiety disorders
Solution Approach 2:
The patent combines nefopam with controlled release delivery systems and potentially other drugs (as mentioned in the summary), creating a composite therapeutic approach that enhances efficacy while reducing side effects
Data Source
AI summary
Nefopam is used for the manufacture of a medicament for the treatment of an affective disorder such as ADD or ADHD.